Bispecific Antibody– tag –
-
7 Structural Lenses Threading 13 Articles: An Integrated Map from Basics to Next-Gen | Bispecific Antibody Drug Series — Synthesis
Across 12 deep-dives we have rebuilt how to think about bispecific antibodies—from molecular geometry to clinical strategy. This index maps every turning point and signals what the next decade will be about. This series, “From Beginner t... -
The Technological Lineage of Bispecifics: 5 Generations of Refinement and the Next Axes | Bispecific Antibody Drug Series B6
Bispecific antibody drugs are now discussed as one of the important modalities in cancer therapy. Bispecific antibody drugs are now discussed as one of the important modalities in cancer therapy. However, this field did not begin in anyt... -
Where Next-Gen Bispecifics Are Heading: 5 Growth Vectors from Structural Evolution and Indication Expansion | Bispecific Antibody Drug Series A6
Bispecific antibody drugs are already beginning to establish a distinct clinical presence, especially in hematologic malignancies, and are starting to build their own place within cancer therapy. Bispecific antibody drugs are already beg... -
Where Will Bispecifics Take the Next Indication: 4 Strategic Forks in Clinical Development | Bispecific Antibody Drug Series B5
Bispecific antibody drugs are a modality in which theoretical appeal alone is not enough; where and how clinical development begins is critically important. Bispecific antibody drugs are a modality in which theoretical appeal alone is no... -
Where Bispecifics Fit in Cancer Therapy: 4 Modality Frames and Substitution Scenarios | Bispecific Antibody Drug Series A5
Bispecific antibody drugs have gained a strong presence within cancer therapy over the past several years. Bispecific antibody drugs have gained a strong presence within cancer therapy over the past several years. However, to truly under... -
Reading the Risk Map of Bispecifics: 5 Lenses on Toxicity, PK/PD, and Development Bottlenecks | Bispecific Antibody Drug Series B4
Bispecific antibody drugs are a modality that often looks highly attractive in theory. Bispecific antibody drugs are a modality that often looks highly attractive in theory. Because they can handle two targets within a single molecule, t... -
Why Adverse Events Occur: Reading 5 Trade-offs at the Efficacy–Safety Intersection | Bispecific Antibody Drug Series A4
Bispecific antibody drugs are a modality with enormous promise in cancer therapy. Bispecific antibody drugs are a modality with enormous promise in cancer therapy. As we have seen from A1 through B3, the strength of this field lies in th... -
How Modality Shapes Pharmacology: 4 Axes Differentiating BiTE, DART, and IgG-like Designs | Bispecific Antibody Drug Series B3
When we look at bispecific antibody drugs, it becomes clear that even though they are grouped under the same label, they can behave very differently as actual medicines. When we look at bispecific antibody drugs, it becomes clear that ev... -
Mapping the Bispecific Landscape: A 3-Axis Reading by Structure, Target, and Indication | Bispecific Antibody Drug Series A3
Bispecific antibody drugs are often discussed as if they were a single technological field. Bispecific antibody drugs are often discussed as if they were a single technological field. In reality, however, their internal diversity is subs... -
5 Judgement Axes Driving Target Selection and Mechanism Optimization in Bispecifics | Bispecific Antibody Drug Series B2
When people think about the design of bispecific antibody drugs, they often focus first on which targets should be combined. When people think about the design of bispecific antibody drugs, they often focus first on which targets should ... -
What Bispecifics Really Are: 3 Lenses Across History, Definition, and Classification | Bispecific Antibody Drug Series A1
Bispecific antibody drugs are now one of the most important themes in the evolution of cancer therapy and antibody therapeutics. Bispecific antibody drugs are now one of the most important themes in the evolution of cancer therapy and an... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 7 – Synthesis: Where We Stand in 2025 and How ADCs May Evolve Toward the 2030s
In Part 1, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we reviewed ADC design—a In Part 1, we explored why the ADC land grab is happening now and how ADCs fit into th... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 6 – Designing Oncology Portfolios Beyond ADCs: Positioning Bispecifics, Cell Therapies, and Radiopharmaceuticals
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we review In Part 1 of this series, we explored why the ADC land grab is happening now and how A... -
Oncology Drug Approval News Flash: FDA Grants Full Approval to Tarlatamab-dlle for ES-SCLC and Accelerated Approval to Sevabertinib for HER2-Mutated NSCLC
On November 19, 2025, the U.S. Food and Drug Administration (FDA) granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen) for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease progressed after platinum... -
[Beginner-Friendly | Bispecific Antibody Drugs] Vol.6: Evolution of Bispecific Antibody Technologies — A Historical Overview of Engineering Breakthroughs
In this final deep-dive of our beginner-friendly bispecific antibody series, we explore the historical trajectory of bispecific antibody (BsAb) technology. In this final deep-dive of our beginner-friendly bispecific antibody series, we e... -
Beginner-Friendly｜Bispecific Antibody Drug Series Vol. 5: Latest Advances and 1-Year Approval Roundup
In this final volume, we summarize the latest developments in bispecific antibody drug R&D by leading biotech and pharma companies, as well as major approvals over the past year in the US and EU. In this final volume, we summarize th... -
Beginner-Friendly｜What Are Bispecific Antibody Drugs? A Thorough Introduction (Part 1)
Introduction: Why Are Bispecific Antibody Drugs Gaining Attention? In recent years, bispecific antibody drugs (BsAbs) have garnered increasing attention in the treatment of cancer, autoimmune diseases, and infectious diseases. In recent ...
1